2,115 press releases in English indexed under biotech & pharma.
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
MILLBRAE, Calif., Oct. 23, 2026 -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
ROCKVILLE, MD, Oct. 23, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors. Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors.
Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge. Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge.
Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights. Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights.
Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors. Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors.
Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage. Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage.
ESMO 2026 abstracts featuring FCS research: 52P, 1017P, 1076TiP, 1021P, 1134eTiP, 1146eTiP, 1594P, 1846P, 3151P, 2216O FORT MYERS, Fla., Oct. 23, 2026 -- Findings from early-phase clinical research conducted with participation from Florida Cancer Specialists & Research...
Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage. Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage.
REDWOOD CITY, Calif., Oct. 23, 2026 -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned.